BF Biosciences Balance Sheet Health

Financial Health criteria checks 5/6

BF Biosciences has a total shareholder equity of PKR2.5B and total debt of PKR2.3B, which brings its debt-to-equity ratio to 91.2%. Its total assets and total liabilities are PKR8.2B and PKR5.7B respectively. BF Biosciences's EBIT is PKR723.0M making its interest coverage ratio -30. It has cash and short-term investments of PKR2.2B.

Key information

91.2%

Debt to equity ratio

PK₨2.26b

Debt

Interest coverage ratio	-30x
Cash	PK₨2.23b
Equity	PK₨2.47b
Total liabilities	PK₨5.69b
Total assets	PK₨8.17b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: BFBIO's short term assets (PKR3.9B) exceed its short term liabilities (PKR3.7B).

Long Term Liabilities: BFBIO's short term assets (PKR3.9B) exceed its long term liabilities (PKR2.0B).

Debt to Equity History and Analysis

Debt Level: BFBIO's net debt to equity ratio (1.3%) is considered satisfactory.

Reducing Debt: BFBIO's debt to equity ratio has increased from 2.2% to 91.2% over the past 5 years.

Debt Coverage: BFBIO's debt is well covered by operating cash flow (20.8%).

Interest Coverage: BFBIO earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 13:25
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BF Biosciences Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Azeem Akhundzada	Sherman Securities (Pvt.) Limited